Pioglitazone / Glimepiride Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 30mg + 4mg
Reference Brands: Tandemact (EU)
Category:
Diabetes
Pioglitazone+Glimepiride is a combination medicine that helps control blood sugar levels. This medicine is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Adequate sugar control lessens your risk of heart attack or stroke also.
Pioglitazone / Glimepiride Tablets is available in Tablets
and strengths such as 30mg + 4mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pioglitazone / Glimepiride Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pioglitazone / Glimepiride Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pioglitazone / Glimepiride is a fixed-dose combination anti-diabetic medication used for the management of type 2 diabetes mellitus. It combines two complementary mechanisms: pioglitazone, a thiazolidinedione that improves insulin sensitivity, and glimepiride, a sulfonylurea that stimulates insulin secretion from the pancreas. Together, these agents help lower blood glucose levels and improve overall glycemic control in patients whose diabetes is not adequately managed by diet, exercise, or monotherapy.
In the United States, this combination is indicated as an adjunct to diet and exercise for adults with type 2 diabetes who are already treated with either a thiazolidinedione or sulfonylurea, or those who have inadequate glycemic control with either drug alone. In the European Union, it is used for patients who cannot tolerate metformin or for whom metformin is contraindicated, particularly in those already receiving a combination of pioglitazone and glimepiride.
The combination is marketed under the brand name Duetact among others and is manufactured by approved pharmaceutical companies globally. Its use requires careful monitoring of blood glucose, and therapy should be tailored to patient-specific needs to optimize efficacy and minimize adverse effects.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing